TICKERNERD
Menu
TENXTENXHealthcare · Biotechnology

TENX Stock Forecast: Tenax Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$1.86
−1.06% on the day

The 10 Wall Street analysts covering Tenax Therapeutics, Inc. hold a median 12-month price target of $5 — +168.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$64.4M
Ticker Nerd rank
18/ 100
Median analyst target
$5.00
Analysts covering
10
Revenue$0.0
Operating income−$18.8M
Net income−$17.8M
Free cash flow−$14.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.7%
1M
+1.1%
YTD
−84.7%
1Y
−74.3%
From 52W high
−89.8%
From 52W low
+36.8%
$1
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TENX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tenax Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
18/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
77
Volatility
66
Quality
54
Accruals
49
Revisions
37
Issuance
24
Momentum
13
Value
11
Growth
10

Size (77): Smaller than most of the companies we track.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TENX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TENX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26TENXHigh $35.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
6 Buy4 Hold0 Sell
Low $4.00Median $5.00High $35.00

The green dot is the last close — the median target sits +168.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
31 Aug 2026GuggenheimDowngradeNeutral—
11 Aug 2026Canaccord GenuityMaintainsBuy—
11 Aug 2026Canaccord GenuityMaintainsBuy$35 → $4.00
11 Aug 2026Chardan CapitalDowngradeNeutral—
11 Aug 2026Chardan CapitalDowngradeNeutral$27 → $5.00
11 Aug 2026Evercore ISI GroupDowngradeIn-Line—
11 Aug 2026Evercore ISI GroupDowngradeIn-Line$39 → $5.00
11 Aug 2026GuggenheimMaintainsBuy—
11 Aug 2026GuggenheimMaintainsBuy$40 → $4.00
10 Aug 2026William BlairDowngradeMarket Perform—
10 Aug 2026William BlairDowngradeMarket Perform—
31 July 2026Chardan CapitalMaintainsBuy—
31 July 2026Chardan CapitalMaintainsBuy$27
29 July 2026Cantor FitzgeraldReiteratesOverweight—
29 July 2026Cantor FitzgeraldReiteratesOverweight$35
28 July 2026Canaccord GenuityInitiatesBuy—
28 July 2026Canaccord GenuityInitiatesBuy$35
22 July 2026Evercore ISI GroupInitiatesOutperform$39
22 July 2026Evercore ISI GroupInitiatesOutperform—
2 July 2026Chardan CapitalMaintainsBuy$27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TENX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TENX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Tenax Therapeutics, Inc. returned −74.3% against +13.1% for the S&P 500, dividends included.

TENX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250Jan 26Apr 26Jul 26Oct 26TENXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TENX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
2
Fundamentals

Tenax Therapeutics, Inc. (TENX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.4×

Cheaper than 69% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 75% of US stocks

EV / EBITDA
0.4×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−59.8%

Higher than 19% of US stocks

Return on assets
−37.7%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tenax Therapeutics, Inc. (TENX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tenax Therapeutics, Inc. has a market value of $64.4M and an enterprise value of −$19.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$64.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$46.0M.

  • Shares outstanding: 26.5M.

  • Trailing P/E: 2.4×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Tenax Therapeutics, Inc. employs 14 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

TENX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TENXTenax Therapeutics, Inc.$64.4M18
MAIAMAIA Biotechnology, Inc.$70.4M27
CGTXCognition Therapeutics, Inc.$71.2M34
CRDFCardiff Oncology, Inc.$69.2M48
NMRANeumora Therapeutics, Inc.$71.6M33
MNOVMediciNova, Inc.$72.2M97
CSBRChampions Oncology, Inc.$67.8M27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tenax Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TENX news & analysis

Lost Money on Tenax Therapeutics, Inc. Shares? The Law Offices of Frank R.

Business Wire · 29 Oct 2026negative

The Law Offices of Frank R. Cruz announced an investigation into potential securities fraud claims on behalf of Tenax Therapeutics investors. The inquiry examines whether the company may have violated federal securities laws, focusing on disclosures about Tenax on August 10, 2026.

Why it matters — The investigation is relevant to TENX watchers because it raises questions about the company’s disclosures and potential investor claims.

TENX Investors Have Opportunity to Lead Tenax Therapeutics, Inc. Securities Fraud Lawsuit

PRNewsWire · 28 Oct 2026negative

Rosen Law Firm announced a class action lawsuit on behalf of purchasers of Tenax Therapeutics securities from November 13, 2023, through August 7, 2026. The firm said the lawsuit has already been filed.

Why it matters — The filing concerns a securities lawsuit involving TENX and purchasers during the stated class period.

FAQ

Frequently asked questions about TENX stock

What is the TENX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Tenax Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $4 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TENX stock a buy right now?

Of the 10 analysts covering Tenax Therapeutics, Inc., 6 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tenax Therapeutics, Inc. 18 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TENX?

As at 28 Oct 2026, Tenax Therapeutics, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (77 of 100).

Will TENX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +168.8% from the last close, and Ticker Nerd's factor model ranks Tenax Therapeutics, Inc. 18 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TENX stock forecast for 2030?

No analyst covering Tenax Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TENX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $35 over the next 12 months.

How has TENX stock performed over the past year?

Tenax Therapeutics, Inc. returned -74.3% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tenax Therapeutics, Inc. do?

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on cardiopulmonary therapies.

What is the latest news on TENX?

The most recent item we track (Business Wire, 29 Oct 2026): "Lost Money on Tenax Therapeutics, Inc. Shares? The Law Offices of Frank R.". The Law Offices of Frank R. Cruz announced an investigation into potential securities fraud claims on behalf of Tenax Therapeutics investors. The inquiry examines whether the company may have violated federal securities laws, focusing on disclosures about Tenax on August 10, 2026.

Company

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on cardiopulmonary therapies. The company develops treatments for serious cardiovascular and pulmonary conditions, with a primary emphasis on pulmonary hypertension associated with heart failure with preserved ejection fraction. Its pipeline includes levosimendan-based programs, as well as other drug candidates aimed at improving outcomes in heart and lung disease. Tenax Therapeutics concentrates on advancing clinical-stage therapies for patients with high unmet medical needs, making it a specialized player in the pharmaceutical market. Headquartered in Chapel Hill, North Carolina, Tenax Therapeutics operates as a research-driven company centered on novel treatments for complex cardiopulmonary disorders.

CEO Mr. Christopher T. Giordano · 14 employees · United States · https://www.tenaxthera.com